Wayland Group Corp. Aktie Canadian Securities Exchange
Aktien
A2PAPZ
CA9442041062
WAYL
Pharmazeutika
Umsatz 2016 | 4.06 5.59 3.74 | Umsatz 2017 | 3.22 4.44 2.96 | Marktwert | 203 Mio. 280 Mio. 187 Mio. |
---|---|---|---|---|---|
Nettoergebnis 2016 | -8 Mio. -11.01 Mio. -7.36 Mio. | Nettoergebnis 2017 | -67 Mio. -92.22 Mio. -61.64 Mio. | EV / Sales 2016 * | - |
Nettoschuld 2016 | 9.13 12.56 8.4 | Nettoliquidität 2017 | 0.42 0.58 0.38 | EV / Sales 2017 | 63’046’727 x |
KGV 2016 * |
-
| KGV 2017 |
-2.13
x | Beschäftigte | - |
Rendite 2016 * |
-
| Rendite 2017 |
-
| Streubesitz | 100% |
Manager | Titel | Alter | Seit |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
% 1. Jan. | Kap. | |
---|---|---|
+39.33% | 6.11 Mrd. | |
-18.38% | 4.35 Mrd. | |
-9.17% | 3.18 Mrd. | |
+3.98% | 3.16 Mrd. | |
-3.41% | 2.51 Mrd. | |
+48.74% | 1.98 Mrd. | |
-4.82% | 1.74 Mrd. | |
-1.24% | 1.63 Mrd. | |
-8.96% | 1.6 Mrd. |